Cost-effectiveness of metacognitive therapy for cardiac rehabilitation participants with symptoms of anxiety and/or depression: analysis of a randomised controlled trial
Authors:
- Gemma E ShieldsGSGemma E Shields
- Elizabeth CamachoECElizabeth Camacho
- Linda M DaviesLDLinda M Davies
- Patrick Joseph DohertyPDPatrick Joseph Doherty
- David ReevesDRDavid Reeves
- Lora CapobiancoLCLora Capobianco
- Anthony HeagertyAHAnthony Heagerty
- Calvin HealCHCalvin Heal
- Deborah BuckDBDeborah Buck
- Adrian WellsAdrian Wells
Open Access
Abstract
Objectives The burden of cardiovascular disease (CVD) is increasing. Cardiac rehabilitation (CR) is a complex intervention offered to patients with CVD, following a heart event, diagnosis or intervention, and it aims to reduce mortality and morbidity. The objective of this within-trial economic evaluation was to compare the cost-effectiveness of metacognitive therapy (MCT) plus usual care (UC) to UC, from a health and social care perspective in the UK. Methods A multicentre, single-blind, randomised controlled trial (ISRCTN74643496) was conducted in the UK involving 332 patients with CR with elevated symptoms of anxiety and/or depression and compared group-based MCT with UC. The primary outcome of the cost-effectiveness analysis was quality-adjusted life-years (QALYs). The time horizon of the primary analysis was a 12-month follow-up. Missing data were imputed using multiple imputation. Uncertainty was explored by probabilistic bootstrapping. Sensitivity analyses tested the impact of the study design and assumptions on the incremental cost-effectiveness ratio. Results In the primary cost-effectiveness analysis, MCT intervention was dominant, with a cost-saving (net cost −£219; 95% CI −£1446, £1007) and QALY gains (net QALY 0.015; 95% CI −0.015, 0.045). However, there is a high level of uncertainty in the estimates. At a threshold of £30 000 per QALY, MCT intervention of around 76% was likely to be cost-effective. Conclusions Results suggest that intervention may be cost-saving and health-increasing; however, findings are uncertain and subject to limitations. Further research should aim to reduce the uncertainty in the findings (eg, with larger sample sizes) and explore potential longer-term economic benefits associated with MCT in this setting.Keywords
Funding Information
- National Institute for Health Research (Programme Grants for Applied Research (PGfAR) Prog)
This publication has 44 references indexed in Scilit:
- Achieving cardiac rehabilitation uptake targets: What is the value case for commissioners? A UK case-studyInternational Journal of Cardiology, 2023
- European Society of Cardiology: cardiovascular disease statistics 2021European Heart Journal, 2022
- Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for TransparencyPharmacoEconomics, 2021
- Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019JACC, 2020
- Current challenges in cardiac rehabilitation: strategies to overcome social factors and attendance barriersExpert Review of Cardiovascular Therapy, 2020
- The Beneficial Effects of Cardiac RehabilitationCardiology and Therapy, 2020
- Cost-Utility Analysis of Home-Based Telerehabilitation Compared With Centre-Based Rehabilitation in Patients With Heart FailureHeart, Lung and Circulation, 2019
- Depression and Anxiety as Predictors of 2-Year Cardiac Events in Patients With Stable Coronary Artery DiseaseArchives of General Psychiatry, 2008
- Psychological interventions for coronary heart disease2004
- Modelling cognition in emotional disorder: The S-REF modelBehaviour Research and Therapy, 1996